Which cancer disease is pirtobrutinib used to treat?

Pirtobrutinib is a new oral Bruton's tyrosine kinase inhibitor (BTK inhibitor), mainly used to treat certain types of hematological malignancies. It provides a new treatment option especially for patients who have previously received BTK inhibitor treatment but whose disease has progressed or developed drug resistance. Pitobrutinib is designed to overcome the resistance issues associated with traditional BTK inhibitors, extending patient survival and improving quality of life.

Clinically, pitobrutinib is mainly used to treat mantle cell lymphoma (MCL), an aggressive non-Hodgkin lymphoma that usually has a poor prognosis and limited treatment options. Since mantle cell lymphoma cells are highly dependent on the activity of the BTK signaling pathway, BTK inhibitors can effectively block the growth and spread of tumor cells. Pitobrutinib has demonstrated promising efficacy in this area, showing high response rates and tolerability, particularly in patients who have failed prior treatment.

In addition, pitobrutinib is also used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These diseases also rely on the BTK pathway to maintain the survival of tumor cells. Pitobrutinib provides new treatment possibilities for patients who experience resistance or side effects during traditional BTK inhibitor treatments. Its non-covalent binding properties allow the drug to remain effective in patients with resistance to BTK mutations, thereby expanding the scope of clinical application.

In general, pitobrutinib mainly focuses on BTK-dependent hematological cancer diseases, especially mantle cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma. With the accumulation of more clinical data, this new generation of BTK inhibitors is expected to become an important therapeutic weapon for patients with refractory or relapsed hematological tumors, bringing patients more opportunities to improve survival and quality of life.

Reference materials:https://go.drugbank.com/drugs/DB17472

xa0